About the Company

金宇博沃润泽生物技术有限责任公司成立于2020年8月,是A股上市公司-金宇生物的全资子公司(生物股份:600201)。
作为托珠单抗的国内首仿企业之一,该产品预计2023年申请上市。与此同时,公司正在全面战略性布局包含免疫、生殖、抗病毒、癌症领域的生物大分子药物的研发和产业化工作。我们将基于丹阳总部建设具有核心产能的生物医药生产基地。
未来,金宇博沃将成为金宇生物在人用生物制品的核心企业平台,因此,我们需要全产业链的优秀人才加入,我们将综合候选人的背景,匹配相应工作岗位并提供有竞争力的薪资和福利待遇。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Related Industry Tags

Tags are auto-annotated by keyword text matching and may be correlated. For reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 17,532万(元)
Legal Representative: 谢雪岑
Date Established:
Credit Code: 91321181MA226DFU11
Registered Address: 镇江市丹阳市开发区生命科学产业园紫苑路168号

People who follow this company also follow

Competitors (Similar Companies)

医药 环氧乙烷 DMF 药用辅料
健康管理 健康科技 保健 预防保健

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates